Market Overview:
The global immunotherapy market is expected to grow at a CAGR of 16.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and technological advancements in the field of immunotherapy. The global immunotherapy market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into monoclonal antibodies (mAbs), therapeutic vaccines, checkpoint inhibitors (CIs), and non-specific immunotherapies. The mAbs segment is expected to account for the largest share of the global immunotherapy market in 2018 owing to their high efficacy and safety profile. Oncology is currently one of the most promising applications for mAbs due to their ability to target various tumor types selectively. The checkpoint inhibitors segment is projected grow at a highest CAGR during forecast period owing its increasing use in treatment regimens for various cancers such as melanoma and lung cancer. By application, oncology held majority share followed by inflammation & autoimmune diseases segments respectively in 2017 Immunotherapy has emerged as an important treatment modality across these segments with growing adoption rates over conventional therapies such as steroids or cytotoxic drugs .
Product Definition:
Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response. The importance of immunotherapy is that it can be used to treat a variety of diseases including cancer, allergies, and autoimmune disorders.
Monoclonal Antibodies:
Monoclonal antibodies are antibody produced by the body's immune system specifically targeting and binding to a specific harmful cell or tissue. There are two types of Monoclonal Antibodies, Humulin (Human insulin) and Cosynthetic.
Therapeutic Vaccines:
Therapeutic vaccines are used for the treatment of diseases caused by germs, such as cholera, influenza (flu), smallpox, and yellow fever. These vaccines consist of weakened or killed germs that can stimulate the immune system to produce antibodies and other substances known as immunoglobulins. The most common way therapeutic vaccine is given is through injections into a vein or muscle.
Application Insights:
Oncology accounted for the largest share of the application segment in 2017. Immunotherapy finds wide applications in cancer treatment, wherein it is used to treat different types of cancers including lung, liver, skin and blood cancer. The rising prevalence of cancer across the globe is boosting its application in immunotherapy. According to WHO, around 1 in 6 people dies from Cancer. In 2018, around 2 million people died due to this disease globally which was a rise of 200 thousand deaths compared with 2017.
The central nervous system (CNS) segment is expected to witness lucrative growth over the forecast period owing to increasing incidence rates of neurological disorders such as Parkinson¢â‚¬â„¢s disease.
Regional Analysis:
North America dominated the global immunotherapy market in 2017. This can be attributed to the presence of key players, high R&D investment by companies, and an increase in FDA approvals for new products. The U.S.
The Asia Pacific region comprises emerging countries such as China.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the major growth drivers for the immunotherapy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This number is expected to rise in the coming years due to factors such as aging population and lifestyle changes. This will create a large pool of patients who can be treated with immunotherapy drugs and drive the growth of this market
- Rising awareness about immunotherapy: The rising awareness about immunotherapy among both healthcare professionals and patients is another major growth driver for this market. Immunotherapy has emerged as an effective treatment option for various types of cancers and its benefits are being increasingly recognized by both doctors and patients alike. This is likely to result in an increase in demand for these drugs in the coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunotherapy Market Research Report
By Type
Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, Non-Specific Immunotherapy
By Application
Oncology, Inflammation, Central Nervous System, Others
By Companies
Abbvie, Amgen, Inc., Biogen, Bristol-Myers Squibb, Celgene, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Abbvie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
181
Number of Tables & Figures
127
Customization Available
Yes, the report can be customized as per your need.
Global Immunotherapy Market Report Segments:
The global Immunotherapy market is segmented on the basis of:
Types
Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, Non-Specific Immunotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Inflammation, Central Nervous System, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbvie
- Amgen, Inc.
- Biogen
- Bristol-Myers Squibb
- Celgene
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Roche
- Abbvie
Highlights of The Immunotherapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Therapeutic Vaccines
- Checkpoint Inhibitors
- Non-Specific Immunotherapy
- By Application:
- Oncology
- Inflammation
- Central Nervous System
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunotherapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immunotherapy is a type of treatment that uses the body's own immune system to fight cancer. Immunotherapy treatments work by stimulating the body's natural defenses against cancer.
Some of the key players operating in the immunotherapy market are Abbvie, Amgen, Inc., Biogen, Bristol-Myers Squibb, Celgene, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Abbvie.
The immunotherapy market is expected to grow at a compound annual growth rate of 16.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunotherapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immunotherapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immunotherapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immunotherapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immunotherapy Market Size & Forecast, 2018-2028
4.5.1 Immunotherapy Market Size and Y-o-Y Growth
4.5.2 Immunotherapy Market Absolute $ Opportunity
Chapter 5 Global Immunotherapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Immunotherapy Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Therapeutic Vaccines
5.2.3 Checkpoint Inhibitors
5.2.4 Non-Specific Immunotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Immunotherapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Immunotherapy Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Inflammation
6.2.3 Central Nervous System
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Immunotherapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Immunotherapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Immunotherapy Analysis and Forecast
9.1 Introduction
9.2 North America Immunotherapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Immunotherapy Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Therapeutic Vaccines
9.6.3 Checkpoint Inhibitors
9.6.4 Non-Specific Immunotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Immunotherapy Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Inflammation
9.10.3 Central Nervous System
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Immunotherapy Analysis and Forecast
10.1 Introduction
10.2 Europe Immunotherapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Immunotherapy Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Therapeutic Vaccines
10.6.3 Checkpoint Inhibitors
10.6.4 Non-Specific Immunotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Immunotherapy Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Inflammation
10.10.3 Central Nervous System
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Immunotherapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Immunotherapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Immunotherapy Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Therapeutic Vaccines
11.6.3 Checkpoint Inhibitors
11.6.4 Non-Specific Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Immunotherapy Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Inflammation
11.10.3 Central Nervous System
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Immunotherapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Immunotherapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Immunotherapy Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Therapeutic Vaccines
12.6.3 Checkpoint Inhibitors
12.6.4 Non-Specific Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Immunotherapy Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Inflammation
12.10.3 Central Nervous System
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Immunotherapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Immunotherapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Immunotherapy Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Therapeutic Vaccines
13.6.3 Checkpoint Inhibitors
13.6.4 Non-Specific Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Immunotherapy Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Inflammation
13.10.3 Central Nervous System
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Immunotherapy Market: Competitive Dashboard
14.2 Global Immunotherapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbvie
14.3.2 Amgen, Inc.
14.3.3 Biogen
14.3.4 Bristol-Myers Squibb
14.3.5 Celgene
14.3.6 Johnson & Johnson
14.3.7 Merck
14.3.8 Novartis
14.3.9 Pfizer
14.3.10 Roche
14.3.11 Abbvie
